The present disclosure relates to mucoadhesive aqueous-based homogenous gel formulations of metronidazole (MTZ) for intravaginal application and their uses, for example to treat bacterial vaginosis. Particular compositions comprise high concentration, high dosage, 1% to 2% by weight formulations providing 60mg-Omg MTZ in a single application. These compositions also reduce the incidence of vulvovaginal candidiasis, which is a common occurrence following treatment for bacterial vaginosis. Compositions also comprise mucoadhesive gelling polymers and a solvent system comprising lower aromatic alcohols, lower alkylene diols and polyoxyalkeylenes, wherein the formulation can be free from solubility enhancers such as dextrins, cyclodextrins, niacin, niacinamide and surfactants.

Download PDF
Document Preview
Document History
  • Publication: Mar 3, 2016
  • Application: Feb 9, 2016
    AU AU 2016/200825 A
  • Priority: Feb 9, 2016
    AU AU 2016/200825 A
  • Priority: Jun 28, 2012
    AU AU 2012/275292 A
  • Priority: Jun 28, 2012
    US US 2012/0044738 W
  • Priority: Jul 14, 2011
    US US 201161508058 P
  • Priority: Jun 28, 2011
    US US 201161502285 P

Sign in to the Lens